Esfam Biotech
Multi-Asset Biopharmaceutical Company Using global expertise, purpose-built AI algorithms and proven science to develop novel biotechnology solutions for global market impact with a focus on significant unmet needs in healthcare.…
Overview
Multi-Asset Biopharmaceutical Company Using global expertise, purpose-built AI algorithms and proven science to develop novel biotechnology solutions for global market impact with a focus on significant unmet needs in healthcare.
Overview:
– Discovered a new treatment paradigm for infectious diseases and cancer.
– Two Drug discoveries that are competitive to current treatments or first in class.
Esfam 289: effective against infectious diseases/viruses (tested in animal & human viral infections). Research continues as a broad-spectrum Antiviral treatment.
Esfam 269: effective against late-stage cancer (expected to be cancer agnostic) potentially broad-spectrum treatment for cancer.
– Wholly owned IP with a significant IP Pipeline.
Progressing lead indications targeting Prostate Cancer; Covid & Long Covid; PRRS.
3 lead indications, ready for toxicology 2024.
4 to 5 years exit strategy on lead indications.
Significant value inflections throughout.
Globally leading Scientific Advisory board.
Global Clinical Research partnerships
Committed Founder, Experienced Executive and Solid Commercial Board.
Addressing global health challenges with substantial markets with first in class market competitive solutions.
Further information in relation to the business and its science data is available. Inquiries can be directed to:
Ms. Penelope Lane BSc Bus, MPH (Eco). Managing Director & CEO
Contact [email protected]